Pharming Group (NASDAQ:PHAR) Shares Up 5.6%

Shares of Pharming Group (NASDAQ:PHAR) were up 5.6% during trading on Monday . The company traded as high as $7.98 and last traded at $7.98. Approximately 1,812 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 4,405 shares. The stock had previously closed at $7.56.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.

Pharming Group Stock Up 4.1 %

The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The company has a fifty day simple moving average of $8.11 and a two-hundred day simple moving average of $9.46. The firm has a market capitalization of $546.83 million, a PE ratio of -50.75 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same period last year, the company earned $0.02 earnings per share. Analysts forecast that Pharming Group will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.